Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: inside layer (24), coating (68), liner (5)

Inotuzumab Ozogamicin

Description: Relapsed or refractory CD22-positive B-Cell acute lymphoblastic leukaemia.
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/ALL/Inotuzumab-Ozogamicin.pdf

Papers Council of Governors 20 July 2022

Description: Agenda attachments 1 CoG Agenda - 20.07.2022.docx Date Time Location Chair Agenda Council of Governors 20/07/2022 14
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2022-Trust-documents/Papers-Council-of-Governors-20-July-2022.pdf

Papers Council of Governors - 27 April 2022

Description: Date Time Location Chair Agenda Council of Governors 27/04/2022 14:00 - 16:00 Microsoft Teams Jane Bailey 1 Chair
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2022-Trust-documents/Papers-Council-of-Governors-27-April-2022.pdf

Durvalumab(28day-1500mg)

Description: Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) Durvalumab (28 day – 1500mg) Regimen • NSCLC - Durvalumab (28 day – 1500mg) Indication • Durvalumab is
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Durvalumab28day-1500mg.pdf

Visiting guidelines: Burley and Lyndhurst wards - patient information

Description: This factsheet outlines the visiting guidelines on the maternity wards at Princess Anne Hospital.
Url: /Media/UHS-website-2019/Patientinformation/Pregnancyandbirth/Visiting-guidelines-Burley-and-Lyndhurst-wards-3137-PIL.pdf

Ipilimumab(1mg/kg)-Nivolumab(3mg/kg)

Description: Chemotherapy Protocol RENAL CANCER IPILIMUMAB (1mg/kg)-NIVOLUMAB(3mg/kg) Regimen • Renal – Ipilimumab (1mg/kg)-Nivolumab (3mg/kg) Indication • Ipilimumab in
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Renal-cell/Ipilimumab1mgkg-Nivolumab3mgkg.pdf

RCVP-Cyclophosphamide-Prednisolone-Rituximab-Vincristine Ver 1.2

Description: Chemotherapy Protocol LYMPHOMA CYCLOPHOSPHAMIDE-PREDNISOLONE-RITUXIMAB-VINCRISTINE (RCVP) Regimen Lymphoma – RCVP-Cyclophosphamide-Prednisolone-Rituximab-Vincristine Indication Non-Hodgkin’s Lymphoma Toxicity
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/RCVP-Cyclophosphamide-Prednisolone-Rituximab-Vincristine-Ver-1.2.pdf

InP-Ifosfamide-Liposomal Doxorubicin (Caelyx) v1

Description: Chemotherapy Protocol SARCOMA IFOSFAMIDE-LIPOSOMAL DOXORUBICIN (Caelyx) In-Patient Regimen Please note this protocol is based on information for the use
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Sarcoma/InP-Ifosfamide-Liposomal-Doxorubicin-Caelyx-v1.pdf

MyelomaMPTMelphalan(PO)PrednisoloneThalidomideVer1

Description: Chemotherapy Protocol MULTIPLE MYELOMA MPT-MELPHALAN (PO)-PREDNISOLONE-THALIDOMIDE Regimen Multiple Myeloma – MPT-Melphalan (PO)-Prednisolone-Thalidomide Indication First line treatment
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaMPTMelphalanPOPrednisoloneThalidomideVer1.pdf

MyelomaCTD21CyclophosphamideDexamethasoneThalidomide(CTD)Ver1

Description: Chemotherapy Protocol MULTIPLE MYELOMA CTD (21)-CYCLOPHOSPHAMIDE-DEXAMETHASONE-THALIDOMIDE (21 days) There are multiple versions of this protocol in use. Please
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaCTD21CyclophosphamideDexamethasoneThalidomideCTDVer1.pdf

351 to 360 of 748

Previous … 34 35 36 37 38 … Next